2012-09-27 18:23:31 - New Pharmaceuticals research report from Datamonitor is now available from Fast Market Research

The increasing prevalence of asthma and launch of new therapies will boost the Chinese asthma market (Tier 1 and Tier 2 cities) from $331m in 2012 to $489m by 2021. A number of novel products will increase the product offering on the market, however, with only a fraction of the patient pool market receiving asthma treatment, considerable untapped patient potential will remain.

Scope
* Access Datamonitor's patient-based asthma market forecast for Chinese Tier 1 and Tier cities, with transparent methodology and clear assumptions.
* Explore the current and future market size of asthma in China and see how pipeline products will impact the market.
* Gain insight into asthma market dynamics in China, and see where untapped market potential remains.
*

Understand which factors are driving growth in the Chinese asthma market, and what challenges marketed and pipeline products face.

Highlights

Datamonitor forecasts the Chinese Tier 1 and Tier 2 asthma market to grow from $331m in 2012 to $489m by 2021. Despite this growth, the asthma market will reach only a fraction of its potential. Still, with a growing patient pool, unique market dynamics, and increasing treatment coverage, the asthma market in China is becoming more attractive.


Full Report Details at
- www.fastmr.com/prod/464851_market_and_product_forecasts_asthma_i ..


Datamonitor expects that four new therapies will enter the Chinese market over 2012-21, including the first once-daily ICS/LABA combinations and biologic anti-asthmatics. While biologics are clinically attractive, their commercial potential will be held back by their relatively high price and limited patient pool.

Datamonitor estimates that in 2012 Seretide and Singulair topped the market with sales of $59m and $65m, respectively, together capturing 37% of the Chinese market (Tier 1 and Tier 2 cities). Datamonitor forecasts that Seretide will face competition from once-daily ICS/LABAs after 2015, but Singulair will maintain its market dominance.

Reasons to Get this Report
* How large is the current asthma market size in Chinese Tier 1 and Tier 2 cities and how is it expected to change over the next 10 years?
* What restrictions will novel therapies face upon launching in the Chinese asthma market?
* How will current market leaders be impacted by additional product launches?
* What role do Chinese regulations play in asthma market dynamics, and how does this impact product use?

Partial Table of Contents:

OVERVIEW

* Catalyst
* Summary

EXECUTIVE SUMMARY

* Strategic scoping and focus
* Datamonitor key findings
* Related reports

MARKET DEFINITION

* Market definition for asthma

* Long-acting beta2 agonists + inhaled corticosteroids (R3F1)
* Anticholinergics + beta2 agonists (R3G4)
* Long-acting beta2 agonists (R3A3)
* Short-acting beta2 agonists (R3A4)
* Inhaled corticosteroids (R3D1)
* Antileukotrienes (R3J2)
* Systemic xanthines (R3B2)
* All other asthma and COPD (R3X2)

* Forecast methodology and assumptions

* Methodology flow
* Regional coverage

* Additional forecast methodology

MARKET OVERVIEW AND CONTEXT

* Reimbursement status
* Product lifecycle
* Current and future market dynamics overview

* Changing class dynamics but ICS/LABAs and antileukotrienes will still lead the asthma market in 2021
* Market set to fragment but Singulair will remain on top

BRAND FORECASTS

* Singulair (montelukast; Merck & Co.)

* Forecast assumptions
* Singulair forecast 2012-21

* Seretide (fluticasone/salmeterol; GlaxoSmithKline)

* Forecast assumptions
* Seretide forecast 2012-21

* Pulmicort (budesonide; AstraZeneca)

* Forecast assumptions
* Pulmicort forecast 2012-21

* Pei Mei Ta Ni (alpha asarone; Guilin Pharma)

* Forecast assumptions
* Pei Mei Ta Ni forecast 2012-21

* Symbicort (budesonide/formoterol; AstraZeneca)

* Forecast assumptions
* Symbicort forecast 2012-21

* An Sai Ma (doxofylline; Heilongjiang Fuhe Huaxing Pharma)

* Forecast assumptions
* An Sai Ma forecast 2012-21

* Relovair (fluticasone furoate/vilanterol; GlaxoSmithKline)

* Forecast assumptions
* Relovair forecast 2012-21

* Xolair (omalizumab; Roche/Genentech/Novartis)

* Forecast assumptions
* Xolair forecast 2012-21

* QMF149 (mometasone/indacaterol; Novartis)

* Forecast assumptions
* QMF149 forecast 2012-21

* Lebrikizumab (Roche/Genentech)

* Forecast assumptions
* Lebrikizumab forecast 2012-21

BIBLIOGRAPHY

* Journal papers
* Websites
* Datamonitor reports

APPENDIX

* Contributing experts
* Forecast methodology

* Volume and value forecast methodology
* Price and compliance assumptions

TABLES

* Table: Reimbursement status of main anti-asthmatic drugs in Tier 1 cities, 2009 and 2010
* Table: Asthma brand sales in Tier 1 and Tier 2 cities in China ($m), 2012-21

FIGURES

* Figure: Patient-based forecast methodology for asthma in China, 2012
* Figure: Total healthcare score in China, by administrative region, 2009
* Figure: Number of physicians involved in the survey, Tier 1 and Tier 2 cities, 2012
* Figure: Number of physicians involved in the survey, Tier 2 and Tier 3 hospitals, 2012
* Figure: Product lifecycles in the EU/US and China, 2012
* Figure: Asthma sales in Tier 1 and Tier 2 cities in China ($m), 2012-21
*

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=464851&dt=t

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.